The Mayo Clinic expert spoke about stem cell transplantation for patients with myeloma and the factors that affect the ability to collect stem cells.
Shaji Kumar, MD, from the Mayo Clinic in Rochester, Minnesota, discussed the importance of stem cell transplantation for patients with myeloma and the steps necessary to perform the procedure at the 2020 Transplantation & Cellular Therapy Meetings, held February 19-23, 2020 in Orlando, Florida.
Transcription:
Stem cell transplantation remains an important part of myeloma therapy in patients who are eligible to go through a stem cell transplant and this often includes patients all the way up to 75 years in age, as long as they have good performance jettison, good organ function. So, the ability to collect stem cells for autologous stem cell transplantation is important in myeloma. There are a variety of different factors that affect the ability to collect stem cells and these include the type and the duration of therapy they receive before they go to a stem cell transplant, and as well as the degree of disease control. In the younger patients, we often try to collect adequate numbers of cells for 2 to 3 stem cell transplantation, which can then be used either as tandem order transplants or salvage order transplant at the time of relapse. So, it’s important we are able to collect adequate numbers and a variety of different approaches have been tried…all of which depends on the particular clinical context.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.